Category Archives: Cell Therapy

From left are Dr. Oz, researcher Sally Temple, patient Patricia Holman, television personality Montel Williams and Dr. Elisabeth Leamy. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researcher Sally Temple, patient Patricia Holman, television personality Montel Williams and Dr. Elisabeth Leamy. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researchers Sally Temple, patient Patricia Holman, Dr. Elisabeth Leamy and television personality Montel Williams. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researchers Sally Temple, patient Patricia Holman, Dr. Elisabeth Leamy and television personality Montel Williams. (Courtesy Sony Pictures Television)

Dr. Oz with Sally Temple, scientific director and co-founder of the Neural Stem Cell Institute. (Courtesy Sony Pictures Television)

Dr. Oz with Sally Temple, scientific director and co-founder of the Neural Stem Cell Institute. (Courtesy Sony Pictures Television)

Local stem cell researcher to appear on Dr. Oz today

Sally Temple has a plea for people considering stem cell therapy to cope with a chronic illness or life-threatening disease: Don't. Not yet.

Temple, co-founder of the Neural Stem Cell Institute in Rensselaer and president of the International Society for Stem Cell Research, has spent her career studying stem cells. Her pre-taped appearance on "The Dr. Oz Show" airs Tuesday, Feb. 14, where she talks about the difference between stem cell research and what she calls the "snake oil" promises of clinics that haven't been approved by the FDA but promise miracle cures for scourges like Alzheimer's and Parkinson's diseases.

Stem cells hold promise for treatment because they are the foundation from which all parts of the human body grow.

There are more than 500 clinics in the country offering unproven therapies, including some in New York state and a lot in Florida. "We know it's going on all around the world," Temple said.

Patients lured by false promises spend a lot of money. Temple said people have taken out second mortgages to cover the costs. But they are also at medical risk, Temple said, because injecting stem cells even the patient's own cells can have unpredictable results.

On TV

The Dr. Oz Show airs at 2 p.m. weekdays on NewsChannel 13 WNYT. Learn more about stem cell research at http://neuralsci.org.

"We're now hearing of people getting dreadful outcomes, tumors and blindness," she said.

It's because, without FDA approval and the long process of testing a new drug, there's no way to know for sure what's in the syringe, Temple said. "It may sound good to take stem cells from your own fat and inject them into your eye, but injecting stem cells that were good at making fat into another part of the body where they were never supposed to be can be disastrous."

Dr. Mehmet Oz said he chose this subject because there are stem cell clinics using the potential of legitimate research to take advantage of patients desperate for help.

"These physicians are violating not only the trust of their patients but also the law and hopefully our show will push the FDA to use its authority to shut them down," Oz said.

Temple said she was impressed by how informed Oz was during the taping for the show in New York City last month, and said it was clear the researchers and producers on the show had done their homework. Montel Williams, a former show host himself, also appeared on the segment. Williams suffers from multiple sclerosis and said he's been approached by clinics who want his celebrity endorsement.

"He was fully aware of lack of research and knew that when you dig for scientific rationale, it's not there," Temple said. "True stem cell therapy is coming, but we have to go through the proper channels and know it's safe."

See the original post here:
Local stem cell researcher to appear on Dr. Oz today - Albany Times Union

Sessions/Tracks

Track 1: Cell Therapy

Cell therapy or cytotherapy is the transfer of cells into a patient with a goal of improving the disease. From beginning blood transfusions were considered to be the first type of cell therapy to be practised as routine. Later, Bone marrow transplantation has also become a well established concept which involves treatment of many kind of blood disorders including anemia, leukemia, lymphyoma and rare immunodeficiency diseases. Alternative medical practitioners perform cell therapy in the form of several different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. It has been claimed by the proponents of cell therapy that it has been used successfully to repair spinal cord injuries, strengthen weaken immune system, treats autoimmune diseases like AIDS, help patients with neurological disorders like Alzheimers disease, parkinsons disease and epilepsy.

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19th International Conference on Cell and Gene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7th Spring Meeting Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.

Track 2: Gene Therapy

Gene therapy basically involves the introduction or alteration of genetic material within a cell or organism with an intention of curing the disease. Both cell therapy and gene therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in DNA or cellular population respectively. The discovery of recombinant DNA technology in the 1970s provided tools to efficiently develop gene therapy. Scientists use these techniques to readily manipulate viral genomes, isolate genes and identify mutations involved in human disease, characterize and regulate gene expressions, and engineer various viral and non viral vectors. Various long term treatments for anemia, haemophilia, cystic fibrosis, muscular dystrophy, Gauschers disease, lysosomal storage diseases, cardiovascular diseases, diabetes and diseases of bones and joints are resolved through successful gene therapy and are elusive today.

Related Conferences

Annual Summit onCell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 3:Molecular Medicine

Molecular Medicineis a branch of medicine that develops ways to diagnose and treat diseases by understanding the ways genes, proteins and other cellular molecules work. It is a broad field where physical, chemical, biological,bioinformatics, and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of the disease, and to develop molecular interventions to correct them. Molecular Medicine has now a days proved to be an exciting field of research as some of the recent advancements has led to improved clinical benefits for human health. These are LPS- induced inflammatory response is suppressed by Wnt inhibitors, Dickkopf-1 and LGK974, Selective inhibition ofEbolaentry with selective estrogen receptor modulators by disrupting the endolysosomal calcium, ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signalling and many more.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 4:Immunotherapy

Due to rapidly advancing field of cancer immunology in past few years, there has been production of several new methods of treating cancer called Immunotherapies. Immunotherapy is a type of treatment that increases the strength of immune response against tumors either by stimulating the activities of specific components of immune system or by counteracting signals produced by cancer cells that suppress immune responses. Some types of immunotherapy are also called as biologic therapy or biotherapy. Recent advancements in cancer immunotherapies have provided new therapeutic approaches. These include tumor-associated macrophages as treatment targets in oncology, in-situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, immune checkpoint blockade and associated endocrinopathies and many more.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Genetic Medicine orMedical Geneticsis the branch of medicine that differs from human genetics, and involves the diagnosis and management of hereditary disorders. Human genetics may or may not apply to medicine, but medical genetics refers to the application of genetics to medical care. Genetic Medicine basically involves different areas such asgene therapy, personalized medicine, predictive medicine and the rapidly emerging new medical specialty. Now a days, medical genetics has wide range of scopes in many conditions involving birth defects and dysmorphology,autism, mental retardation, skeletal dysplasia, mitochondrial disorders, cancer genetics, connective tissue disorders and some more.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 6: Clinical Trials in Cell and Gene Therapy

A clinical trial is a research study that tests how well new medical approaches work on people and determines if a treatment is safe and effective. The new cell and gene therapies (CGTs) that are advancing from the laboratory into early phase clinical trials has proven to be a complex task even for experienced investigators . As a result of wide variety of CGT products and their potential applications, a case by case assessment is warranted for the design of each clinical trial. Some of the latest and advanced clinical trials include safety and efficacy trial of AAV gene therapy in patients with CNGA3 Achromatopsia, A clinical trial for treatment of Aromatic L- Amino acid Decarboxylase (AADC) deficiency using AAV2-hAADC- An expansion and Glypican 3-specific Chimeric antigenic receptor expressed in T cells for patients with pediatric solid tumors.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 7: Cell Therapy Bioprocessing

Cell Therapy Bioprocessing activity mainly focuses to accelerate the safe, cost- effective translations and clinical efficacious of cell therapies into commercial products. This activity covers the entire range of cell therapy activities as well as tissue engineering. In order to succeed, commercial success of at least a few late-stage products are required to develop which will be funded to develop next generation tools and technologies for this field. Recent achievements include, preclinical filing for Phase 1 clinical trials for cell therapy in acute spinal cord injury, clinical proof of concept studies in tissue- engineered trachea, clinical trials for tissue-engineered larynx and routine clinical practice in the regeneration of corneas. The future research priorities will focus on novel cell and bioprocess engineering techniques in order to improve the manufacturing efficacy and methods for health technology assessment to support rapid clinical adoption of new cell therapies.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cell and Gene Therapy products manufacturing focuses on various strategies like the manufacturing process must protect the product, patient, should focus on product characterization, process control, high throughput and parallel processing to achieve scale. The process/analytical development throughout clinical trials involve ongoing, iterative development of manufacturing process and characterization of profile and FDA expecting increasing control and characterization as clinical development progresses. Steps involved in individualized manufacturing and running in parallel for high throughput involves cell selection, expansion, activation, centrifugation and cryopreservation.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 9: Rare Diseases & Orphan drugs

Rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10,000 persons in the European Community according to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare if taken individually but they affect a significant proportion of the European population when considered as a single group. Several initiatives have been taken at international, European and national level to tackle public health as well as research issues related to diagnosis, prevention, treatment and surveillance of these diseases. An Orphan drug can be defined as the one that is used to treat an orphan disease. An orphan disease in USA is defined as the one that affects fewer than 200000 individuals, but in Japan the number is 50,000 and in Australia is 2000. In past 20 years efforts have been made to encourage companies to develop orphan drugs. The Orphan Drug Act in the USA (1983) was succeeded by similar legislation in Japan (1985), Australia (1997), and the European Community (2000). The encouragement takes three forms: tax credits and research aids, simplification of marketing authorization procedures, and extended market exclusively.

Related Conferences

Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Stem cells can self renew themselves and differentiate or develop into more specialised cells. They are the foundation for every organ and tissue in our body. Due to this ability of the stem cells, they have tremendous promise to help us understand and treat a wide range of diseases, injuries and other health related problems. Bone marrow transplantation is the most widely used stem cell therapy , but some of the therapies are derived from umbilical cord blood are also in use today. Likewise, blood stem cells are used to treat diseases of blood, a therapy that has saved thousands of lives of children with leukemia. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues and the healing process relies on stem cells with implanted tissue.Regenerative medicines aims to replace tissues or organs that have been damaged by disease, trauma, or congenital issues which is in contrast to the current clinical strategy that focuses primarily on treating the symptoms. These regenerative medicines have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, and neuro degenerative diseases. Cell treatment is the quickest developing fragment of regenerative drug and this undeveloped cell treatment is making up the biggest part of this business sector.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cancer is a process where the cells grow aberrantly and this growth of cancer cells results in damage of normal tissues, causing loss of function and often pain. The cancer therapeutic drugs are those drugs that block the growth and spread of cancer by interfering with specific molecules (molecular targets) that are involved in the growth, progression and spread of cancer. Moreover, gene therapy approaches may be designed to directly kill tumor cells using tumor killing viruses, or through the introduction of genes termed as suicide genes into the tumor cells. The Food and Drug Administration (FDA) has approved many cancer therapies in order to treat specific types of cancers. To develop targeted therapies it requires the identification of good targets that is, those targets that play a key role in cancer cell growth and survival. One way to identify potential targets is to compare the amounts of individual proteins in cancer cells with those present in normal cells. Gene silencing has also been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth, blood vessel formation and allow resistance for chemotherapy.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 12:Nuclear Medicine

Nuclear medicineis a branch of medical imaging that involves the application of radioactive substances called radiotracers that are generally injected into the bloodstream, inhaled or swallowed. Theradiotracerthen travels through the area being examined and gives off energy in the form of gamma rays, which are detected by a special camera and a computer to create images of inside the body. It is used to diagnose or determine the severity of or treat different types of diseases like many types of cancers, heart disease, neurological disease, gastrointestinal disease, and other abnormalities inside the body. As nuclear medicine techniques are able to identify molecular activity within the body, they offer the capability to detect diseases in its very early stages as well as a patients immediate response to therapeutic interventions. There are two most common imaging methods in nuclear medicine, one isSingle Photon Emission Computed Tomographyor SPECT and the other is Positron Emission Tomography or PET scans.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 13: Advances in Cell Engineering, Imaging and Screening

In recent times, advancements in cell engineering, imaging and screening has reached a great height in the field of science & technology and also in the business world. It has attracted many scientists from academia and also established or emerging companies in the field to present their latest scientific achievements and exciting technological solutions through presentations in several sessions. This has helped in improving the scientific knowledge among the people, scientists, researchers and exhibitors from all over the world thus enhancing their scientific curiosity and providing robust solutions against technological issues.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Track 14: Synthetic Biology and Genetic modifications of cells

Synthetic Biology is one of the emerging field of research that can be broadly described as the design and construction of novel artificial biological pathways, organisms or devices or the redesigning of existing natural biological systems. Genome editing with engineered nucleases is a type of genetic engineering in which DNA is either inserted, replaced or deleted in the genome of an organism using engineered nucleases or molecular scissors. These nucleases hence create site specific double stranded breaks (DSBs) at desired locations in the genome. The induced double stranded breaks are repaired through non homologous end- joining (NHEJ) or homologous recombination (HR), thus resulting in targeted mutations (edits). Scientists now a days use various engineered nucleases in order to bring desired changes in the human genome.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Biobanking 2016

Sensing the raising importance of Biobanks,Conference LLChosted the 2nd International Conference & Exhibition on Tissue Preservation and Biobanking(Biobanking-2016), duringSeptember 12-13, 2016inPhiladelphia, USAwith a theme Global Innovations in Tissue preservation and Biobanking Technologies. Benevolent response and active participations were received from the Editorial Board Members of Conference LLC Journals as well as from the Biobank project managers, Embryologists, Hematologists, Stem Cell researchers, Scientists, Doctors, Students and Leaders from the fields of Cell and Stem Cell Research, who made this event inspiringly successful.

TheBiobanking-2016 Conferencewas carried out through various sessions with discussions on the following thought provoking and cerebrating scientific tracks:

Human cancer biobank

Biorepository & Biospecimen

Disease based biobank

Cryopreservation Methods

Vitrification

Brain Banking

Biobank Ethics

Biobank in Microbiology

Next Generation Biobanking

Biobank in Genomics

Fertility biobanks

Germplasm Bank

Immune banking

Biobank Applications

Biobanking Informatics

Market Analysis in Biobanking

Tissue engineering

. Stem cell Biobanking

The Organizing Committee would like to thank the moderatorDr.Mary A Hall,UT health sciences, USAandDr. Elena Salvaterra,Air liquide Sanit Service, Italyfor their contribution which resulted in smooth functioning of the conference.

The conference was initiated and embarked with an opening ceremony followed by Keynote presentations, workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The peerless people who promulgated the theme with their Keynote presentations were;

Kelvin GM Brockbank-Ice-free banking by vitrification of tissues(Tissue Testing Technologies LLC, USA)

Simone Chevalier- The Quebec procure prostate cancer biobank: A unique resource for comprehensive studies of the disease(McGill Urology Director of Research, Canada)

Stephen C Peiper-Biospecimen repository genomic annotations in the precision medicine era(Thomas Jefferson University, USA)

Fiorella Guadagni-Biobanks as a pivotal research infrastructure in precision medicine (San Raffaele Rome University, Italy)

Yoed Rabin-Mechanical stress and structural integrity in vitrification(Carnegie Mellon University, USA)

Mitchel C. Schiewe-Applying the KISS principle with vitrification: Safety and quality control concerns in assisted reproductive technologies(Ovagen Fertility, USA)

Various sessions were chaired and co-chaired by: Kelvin GM Brockbank (Tissue Testing Technologies LLC, USA);Simone Chevalier (McGill Urology Director of Research, Canada), USA; Charles W Wang, (Shanghai Jiao Tong University, China);Yaffa Rubinstein (National Institute of Health, USA).

Conference Series LLC has taken the privilege of felicitating Biobanking-2016 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this conference.

The esteemed guests, keynote speakers and researchers shared their innovative research and vast experience through their informative presentations at the podium ofBiobanking-2016.We are glad to inform that all accepted abstracts for the conference have been published inJournal of Tissue Science & Engineering: Open Accessas a special issue.

We are also obliged to various experts, company representatives and other eminent scientists who supported the conference by facilitating the discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference,Conference Series LLC would like to proudly announce the commencement of the 3rd International Conference & Exhibition on Tissue Preservation and Biobanking" to be organized duringAugust 23-24, 2017atSan Francisco, USA.

Mark your calendars for the upcoming Conference; we are hoping to see you soon!

For more details:http://biobanking.conferenceseries.com/

See more here:
Annual Summit on Cell Therapy and Molecular Medicine ...

(This story originally appeared as exclusive content on the Verizon INDYCAR Mobile app. To download the app for smartphones, click here.)

AVONDALE, Ariz. At 82, A.J. Foyt's body has literally been beaten beyond his years.

The first four-time winner of the Indianapolis 500 has experienced everything from a broken back at a 1964 NASCAR race in Riverside, California, to two badly broken feet and legs in a horrible crash at Road America in a 1991 Indy car race.

Foyt retired from racing on pole qualifying day at the 1993 Indianapolis 500, but retirement hasn't been much easier. He was stung more than 200 times from an attack of killer bees in 2005, trapped under an overturned bulldozer on his Texas ranch in 2007 and had knee replacements and a hip replacement. In November 2014, Foyt underwent triple-bypass heart surgery and remained in the hospital for weeks afterward because of complications.

Foyt has survived it all but not without a struggle. He now is looking for a fountain of youth and told the Verizon INDYCAR Mobile App that he will undergo stem cell therapy in Cancun, Mexico.

They have to cut away some of the tissue from my stomach and it takes 8-10 weeks for it to grow back to produce the stem cells, Foyt said in an exclusive interview. I'll probably have it done soon so that we can begin the treatment within the next two to three months.

Adult stem cells are able to grow and become a cell for a specific tissue or organ, according to the National Institutes of Health. They are different from embryonic stem cells, which come from fertilized eggs or aborted fetuses. Embryonic stem cells can turn into cells for nearly any tissue in the body.

The procedure is not performed in the United States, so Foyt has found a medical facility in Mexico that can do the treatment that regenerates newer and younger cells. He said he will have stem cells injected into each ankle and shoulder, as well as into his blood.

It used to be you would have to go to Germany to get this procedure, but now it's available in Cancun and that is probably where I'll have it done, Foyt said Saturday during the Verizon IndyCar Series open test at Phoenix Raceway. I'm not in good health like I used to be and, if my son Larry hadn't taken over (running) the team four years ago, I would have had to shut it down. It's something he likes to do and I'm backing him 100 percent.

Foyt said he feels good to be his age after all the crap that I've been through.

I feel better this year than I did last year, Foyt continued. If I get to feeling bad, I probably won't show up at the race. But I'm going to do that stem cell deal. My wife, Lucy, has been pretty sick lately. Dan Pastorini (the former NFL quarterback) did it and it helped him. Peyton Manning (the former Indianapolis Colts and Denver Broncos quarterback) did it for his neck and it really helped him. Tony Dorsett (the former Dallas Cowboys running back) did it, so I think we should try it.

Go here to read the rest:
INDYCAR legend Foyt plans to have stem cell therapy - INDYCAR

Amsterdam-based Kiadis Biopharma has received Health Canada approval to initiate a global Phase III trial for an allogenic stem cell therapy for acute leukemia.

Kiadis cell therapy, ATIR101 (Allodepleted T-cell ImmunotheRapeutics) is a modified infusion of a family members donated lymphocytes Kiadis is developing to treat leukemia.

By treating the donor cells, the firm looks to reduce the risk of the patient developing severe Graft-versus-Host-Disease, a life-threatening immune response.

Using the contract research organisation (CRO) CTI Clinical Trial and Consulting Services Inc., the trial will enrol 195 patients across 40-50 clinical sites, including the US and Canada.

Kiadis has since submitted the trial protocol to the US FDA and several European regulators, with anticipated launch of ATIR101 in 2018.

The contract manufacturing organisation PCT LLC has been partnered with Kiadis for producing ATIR101 for the US and Canada since June last year, using PCTs Allendale, New Jersey facility.

For the European supply of the therapy, Kiadis will continue to work with the German Red Cross Blood Donor Service, Baden-Wrttemberg-Hessen e.V.,which provided GMP manufacturing services for the Phase II trial of ATIR101.

Manfred Rdiger, CEO of Kiadis Pharma said We have significant momentum now and the preparation of our MAA submission to EMA is progressing well.

Kiadis declined to comment further.

Excerpt from:
Dutch Biopharma launches Phase III trial of Leukemia donor cell therapy - BioPharma-Reporter.com

Hongyun Huang,1 Lin Chen,2 Qingyan Zou,3 Fabin Han,4 Tiansheng Sun,5 Gengsheng Mao,1 Xijing He6

1Institute of Neurorestoratology, General Hospital of Armed Police Forces, 2Department of Neurosurgery, Yuquan Hospital, Tsinghua University, Beijing, 3Guangdong 999 Brain Hospital, Guangzhou, 4Centre for Stem Cells and Regenerative Medicine, Affiliated Hospital of Taishan Medical University, Liaocheng, Shandong, 5Department of Orthopedics, Beijing Army General Hospital, Beijing, 6Second Department of Orthopedics, The Second Affiliated Hospital of Xian Jiaotong University, Xian, Peoples Republic of China

On behalf of the Chinese Association of Neurorestoratology and Chinese Branch of the International Association of Neurorestoratology

Abstract: Cell therapy has been shown to be a key clinical therapeutic option for central nervous system disease or damage, and >30 types of cells have been identified through preclinical studies as having the capacity for neurorestoration. To standardize the clinical procedures of cell therapy as one of the strategies for treating neurological disorders, the first set of guidelines governing the clinical application of neurorestoration was completed in 2011 by the Chinese Branch of the International Association of Neurorestoratology. Given the rapidly advancing state of the field, the Neurorestoratology Professional Committee of Chinese Medical Doctor Association (Chinese Association of Neurorestoratology) and the Chinese Branch of the International Association of Neurorestoratology have approved the current version known as the Clinical Cell Therapy Guidelines for Neurorestoration (China Version 2016). We hope this guideline will reflect the most recent results demonstrated in preclinical research, transnational studies, and evidence-based clinical studies, as well as guide clinical practice in applying cell therapy for neurorestoration.

Keywords: cell therapy, neurorestoration, China, clinical application

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View post:
Clinical cell therapy guidelines for neurorestoration (China version 2016) - Dove Medical Press

Kansas Regenerative Medicine Center (KRMC) staff will be the guest speakers at the next Healthwise 55 luncheon. Speakers Frank Lyons, MD; John Farley (Founder); and Kate Farley will define stem cells and explain their many therapeutic uses. The KRMC staff will also share how stem cell therapy is a potential alternative to joint replacements or other medical therapies.

The event will be on Thursday, February 23, from noon to 1 p.m. in the Conklin Conference Center at Memorial Hospital, located at 511 N.E. 10th, Abilene. The cost is $5.00 to cover the price of the meal. Please call Michelle McClanahan, MHS Director of Volunteer Services, at (785) 263-6692 by Monday, February 20, to make a reservation.

Healthwise 55 is a luncheon and health information program hosted by the MHS Volunteer Corps. It is open to the public for individuals ages 55 and older. It includes a meal followed by a health care professional(s) speaking on a health-related topic.

Originally posted here:
Educational seminar on stem cell therapy to be featured at lunch meeting in Abilene - Salina Post

1102 Bates Street, Suite 1670

Houston, Texas 77030

The GMP Facilities at the Center for Cell and Gene Therapy at Baylor College of Medicine are among the largest and most modern in the United States. Manufacturing of therapeutic biologics has existed at Baylor for more than twenty years, and is now centralized in 19,000 square feet on the 16th floor of the Feigin Center at Texas Childrens Hospital.

This facility opened in 2010 and contains 22 ISO 7 clean room suites supported by dedicated space for cell and product cold storage, flow cytometric analysis, quality control testing, data management and storage and quality assurance activities. The staff has extensive experience in GMP manufacturing of a wide variety of products and intermediates for cellular therapies and of viral and non-viral vectors, and master and working cell banks.

Manufacturing and testing supports more than 30 investigator-sponsored INDs conducted at the Texas Medical Center and institutions around the United States. Products have also been prepared under contract for researchers in Europe, Asia and Australia. The range of products that have been manufactured is shown under the Vector and Cell Therapy Facilitypages.

The facility is also accredited by the Foundation for the Accreditation of Cellular Therapy (FACT)and is CLIA registered for high complexity testing.

Center for Cell & Gene Therapy - cGMP Facilities

Link:
Center For Cell & Gene Therapy - Cell Therapy

US regulators have cleared French biotech Cellectis to trial its off-the-shelf blood cancer cell therapy, UCART123.

The product consists of T-cells modified to target the CD123 antigen on the surface of cancerous cells.

Jennifer Moore, VP of Communications at Cellectis, told us: "CELLforCURE, the largest commercial industrial facility for the production of innovative therapeutic cell therapies in Europe, a subsidiary of the biopharmaceutical group LFB, will perform the cGMP manufacturing of clinical batches of Cellectis allogeneic CART cells."

Unlike autologous cell therapies that are made from the specific patients own cells, UCART123 is composed of lymphocytes harvested from an unrelated, so called universal donor.

The advantage of this allogenic approach is that developers can make and store stocks of cell therapies rather than having to produce a specific batch for each patient, which makes such treatments cheaper according to Loan Hoang-Sayag, Cellectis Chief Medical Officer.

Hoang-Sayag said: Cellectis allogeneic UCART products have the potential to create an important shift with regard to availability, and cost-effectiveness, to make these therapies widely accessible to patient population across the world.

Gene editing

UCART123 - which Cellectis claims is the first allogenic cell therapy to be approved for trials by the US Food and Drug Administration (FDA) -will be tested as a treatment for patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The Phase I clinical studies due to start in the first half of the year.

Like other therapies in Cellectis pipeline, UCART123 is produced using Talen gene editing to inset genes that encode a chimeric antigen receptor (CAR) that targets the CD123 antigen.

The gene editing method is also used to prevent the T-cells of which UCART123 is composed from interacting with non-target proteins, thereby reducing side-effects

UCART therapies

One of Cellectis UCART therapies was used to successfully treat a baby girl with leukaemia whose disease had progressed despite chemotherapy.

According to the results of a study published in 2015 , the girl received a single dose (4.5x106/kg) of Cellectis allogeneic engineered T-cell product UCART19 and two months later the girl was cleared of leukaemia.

Original post:
Cellectis gets US ok to test its universal donor cancer cell therapy - BioPharma-Reporter.com

Isogenica has licensed its synthetic llama antibody library to Maverick Therapeutics, which develops cancer T-cell therapies designed to reduce side effects.

Isogenica is a synthetic biology company near Cambridge that develops libraries of therapeutic antibodies. The biotech has granted US-based Maverick Therapeutics licenses to its llamdA VHHantibody library for the discovery, development and commercialization of therapeutic products. In exchange, it will receive upfront, annual and milestone payments as the antibodies are developed by the client.

Isogenicas llamdA VHH library comprisessingle domain llama antibodies created and screened in vitro,which consumes half the time and creates greater diversity than immunizing llamas. According to the company, its llamdA system routinely interrogates the equivalent to the whole antibody repertoire of one million llamas.

Maverick Therapeutics is a very young biotech, spun out from Harpoon Therapeuticsjust last year. The company is backed by MPM Capital, a USVC managed by biotech veteran Patrick Bauerle from Munich.

The company is developing a unique approach to T-cell cancer therapy. Its antibodies are designed to be inactive when administered and only activate in the tumor microenvironment. This way, theT-cells do not attack healthy tissues, avoiding side effects. Japanese big pharma Takeda recently offered the young company 117M ($125M) to develop this technology.

Mavericks approach looks promising since severe side effects are common in T-cell therapies such asCAR-T, with some companies reporting thedeathof several patients. Other companieslike the French Cellectis and Stimunity are also developing their own strategies to increase the safety of CAR-T.

If successful, the development of Isogenicas antibodies by Maverick could bring the British biotech revenues to accelerate the launch of its new library of fully synthetic human antibodies.

Images from Sergey Didenko /Shutterstock

Originally posted here:
British Synbio's Llama Antibodies recruited for Cancer T-Cell Therapy - Labiotech.eu (blog)

Cellectis has won U.S. regulatory approval to run an early clinical trial using its gene edited cell therapy product UCART123 for blood cancers, boosting the French biotech firm's ambitions in the hot area of cancer research.

Following approval from the Food and Drug Administration, Phase I clinical trials will start in the first half of this year, the company said on Monday.

It marks the first time that U.S. regulators have approved clinical testing of an allogeneic, or "off-the-shelf", gene-edited CAR T cell treatment.

The idea of genetically altering immune cells called T cells so that they can attack cancers more effectively has attracted interest from a range of drugmakers.

But while rivals such as Novartis, Juno and Kite have treatments that use modified T cells extracted from individual patients, Cellectis products are derived from healthy donors and aim to be universal.

Its first such "off-the-shelf" cell therapy UCART19, which is being developed with Servier and Pfizer, is now being tested in Phase I trials in Britain for acute lymphoblastic leukaemia and chronic lymphocytic leukaemia.

It has already rescued two babies treated at London's Great Ormond Street Hospital from previously incurable cancer.

UCART123, which is still wholly owned by Cellectis, is designed to help patients with acute myeloid leukaemia and blastic plasmacytoid dendritic cell neoplasm.

(Reporting by Ben Hirschler; Editing by Ruth Pitchford)

(Reuters Health) - Young people may be at risk for HIV infection, but very few get tested, partly because it can be difficult to access testing, researchers say.

(Reuters Health) - One in four teens who use electronic cigarettes have tried dripping liquid nicotine directly onto the heating coils on the devices to get thicker clouds of vapor, a new study suggests.

TOKYO Japan Tobacco Inc said it was still confident about the prospect of its Ploom Tech tobacco-based electronic cigarettes, the launch of which has been delayed due to supply problems, and raised its dividend despite forecasting a lower annual profit.

Here is the original post:
Cellectis gets US go-ahead to test 'off-the-shelf' cell therapy - Reuters